The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A Potentially Novel Therapy for Graft-Versus-Host Disease

References

• Ferrara J., Burakoff S. The pathophysiology of acute graft‐versus‐host disease in a murine bone marrow transplant model. Graft‐versus‐Host Disease: Immunology, Pathophysiology, and Treatment, S. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Dekker, New York, NY 1990; 9
   Google Scholar
• Vogelsang G. B., Hess A. D. Graft‐versus‐host disease: New directions for a persistent problem. Blood 1994; 84: 2061–2067
   PubMed Web of Science ®Google Scholar
• Dietrich P. Y., Caignard A., Lim A., Chung V., Pico J. L., Pannetier C., Kourilsky P., Hercend T., Even J., Treibel F. In vivo T‐cell clonal amplification at time of acute graft‐versus‐host disease. Blood 1994; 84: 2815–2820
   PubMed Web of Science ®Google Scholar
• Korngold R., Wettstein P. J. Immunodominance in the graft‐versus‐host response to minor histocompatibility antigens. J. Immunol. 1990; 145: 4079–88
   PubMed Web of Science ®Google Scholar
• Wettstein P. J., Korngold R. Immunodominance in the T cell responses to multiple non H‐2 histocompatibility antigens, IV. Partial tissue distribution and mapping of immunodominant antigens. J. Immunol. 1987; 139: 2166–2171
   PubMed Web of Science ®Google Scholar
• Korngold R. Pathophysiology of graft‐versus‐host disease directed to minor histocompatibility antigens. BMT 1991; 7(Suppl 1)38–41
   Google Scholar
• Hamilton B. L., Parkman R. Acute and chronic graft‐versus‐host disease induced by minor histocompatibility antigens in mice. Transplantation 1983; 36: 150–155
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft‐versus‐host disease and graft‐versus‐leukemia reactivity after transplantation of MHC‐compatible bone marrow. Bone Marrow Transplantation 1991; 8: 51–58
   PubMed Web of Science ®Google Scholar
• van Els C. A.C.M., Bakker A., Zwinderman A. H., Zwaan F. E., van Rood J. J., Goulmy E. Effector mechanisms in graft‐versus‐host disease in response to minor histocompatibility antigens, II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990; 50: 67–71
   PubMed Web of Science ®Google Scholar
• Bunjes D., Theobald M., Nierle T., Arnold R., Heimpel H. Presence of host‐specific interleukin‐2 T helper cell precursors correlates closely with active primary and secondary chronic graft‐versus‐host disease. BMT 1995; 15: 727–32
   Google Scholar
• Niederweiser D., Grassegger A., Auböck J., Herold M., Nachbaur D., Rosenmayr A., Gächter A., Nussbaumer W., Gaggi S., Ritter M., Huber C. Correlation of minor histocompatibility antigen‐specific cytotoxic T lymphocytes with graft‐versus‐host disease status and analyses of tissue distribution of their target antigens. Blood 1993; 81: 2200–8
   PubMed Web of Science ®Google Scholar
• Metlay J. P., Pure E., Steinman R. M. Control of the immune response at the level of antigen‐presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Advances in Immunology 1989; 47: 45–116
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261–3282
   PubMed Web of Science ®Google Scholar
• Sinigaglia F., Hammer J. Defining rules for the peptide‐MHC class II interaction. Current Opinion Immunol. 1994; 6: 52–56
   PubMed Web of Science ®Google Scholar
• Sant A. J., Miller J. MHC class II antigen processing: biology of invariant chain. Current Opinion Immunol. 1994; 6: 57–63
   PubMed Web of Science ®Google Scholar
• Loss G. E., Elias C. G., Fields P. E., Ribaudo R. K., McKisic M., Sant A. J. Major histocompatibility complex class II‐restricted presentation of an internally synthesized antigen displays cell‐type variability and segregates from the exogenous class II and endogenous class I presentation pathway. J. Exp. Med. 1993; 178: 73–85
   PubMed Web of Science ®Google Scholar
• Loss G. E., Sant A. J. Invariant chain retains MHC class II molecules in the endocytic pathway. J. Immunol. 1993; 150: 3187–3187
   PubMed Web of Science ®Google Scholar
• Schultz K. R., Paquet J., Abbott G., Bader S., HayGlass K. T. Requirement For B Cells in T cell priming to minor histocompatibility antigens and induction of graft‐versus‐host disease. BMT 1995; 16: 289–95
   Google Scholar
• Bader S., Bugar J., Schultz K. R. Effect of donor dendritic cell depletion on graft‐versus‐host disease secondary to minor histocompatibility (MiHC) antigen differences. J. Hematotherapy 1995; 4: 208, Abstract
   Google Scholar
• Krenger W., Snyder K., Smith S., Ferrara J. L. Effects of exogenous interleukin‐10 in a murine model of graft‐versus‐host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251–7
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Smith S., Valler D. A. Interleukin‐10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842–51
   PubMed Web of Science ®Google Scholar
• Schlegel P. G., Aharoni R., Smilek D. E., Fernandez L. P., McDevitt H. O., Tran N., Vaysburd M., Chao N. J. Prevention of Graft‐versus‐Host Disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84: 2802–2810
   PubMed Web of Science ®Google Scholar
• Schlegel P. G., Vaysburd M., Chen V., Butcher E. C., Chao N. J. Inhibition of T cell costimulation by VCAM‐1 prevents murine graft‐versus‐host disease across minor histocompatibility antigens. J. Immunology 1995; 155: 3856–65
   PubMed Web of Science ®Google Scholar
• Van Gool S. W., de Boer M., Ceuppens J. L. The combination of anti‐B7 monoclonal antibody and cyclosporin A induces alloantigen‐specific anergy during a primary mixed lymphocyte reaction. J. Exp. Med. 1994; 179: 715–201
   PubMed Web of Science ®Google Scholar
• Lombard‐Platlet S., Bertolino P., Deng H., Gerlier D., Rabourdin‐Combe C. Inhibition by chloroquine of the class II histocompatibility complex‐restricted presentation of endogenous antigens varies according to the cellular origin of the antigen‐presenting cells, the nature of the T‐cell epitope, and the responding cell. Immunology 1993; 80: 566–573
   PubMed Web of Science ®Google Scholar
• Humbert M., Raposo G., Cosson P., Reggio H., Davoust J., Salamero J. The invariant chain induces compact forms of class II molecules localized in late endosomal compartments. Eur. J. Immunol. 1993; 23: 3158–66
   PubMed Web of Science ®Google Scholar
• Mizuochi T., Yee S. T., Kasai M., Kakiuchi T., Muno D., Kominami E. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunology Letters 1994; 43: 189–93
   PubMed Web of Science ®Google Scholar
• Maric M. A., Taylor M. D., Blum J. S. Endosomal aspartic proteinases are required for invariant‐chain processing. Proc. Natl. Acad. Sci. USA 1994; 91: 2171–2175
   PubMed Web of Science ®Google Scholar
• Carrasco‐Marin E., Alvarez D. C., Leyva C. F. Wortmannin, in inhibitor of phospholipase D activation, selectively block major histocompatibility complex class II‐restricted antigen presentation. Eur. J. Immunol. 1994; 24: 2031–39
   PubMed Web of Science ®Google Scholar
• Kleijmeer M. J., Ossevoort M. A., van Ossevoort V. C., et al. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J. Immunol. 1995; 154: 5715–24
   PubMed Web of Science ®Google Scholar
• Koch N., Moldenhauer G., Hofmann W. J., Moller P. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II‐associated invariant chain (CD74). J. Immunol 1991; 147: 2643–2651
   PubMed Web of Science ®Google Scholar
• Sperber K., Quaraishi H., Kalb T. H., Panja A., Stecher V., Mayer L. Selective regulation of cytokine secretion by chloroquine: Inhibition of IL‐1 and IL‐6 by monocytes and T cells. J. Rheumatol. 1993; 20: 803
   PubMed Web of Science ®Google Scholar
• Ngheim L. N., Banfalvi G., Csuka I., Olah I., Antoni F. In vitro effect of emetine and chloroquine on the macro‐molecular biosynthesis of murine thymus cells. Acta Biochim. et Biophys. Hungarica 1987; 22: 75–83
   PubMedGoogle Scholar
• Schultz K. R., Nelson D., Bader S. Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplantation
   Web of Science ®Google Scholar
• Wallace D. J. Antimalarial agents and lupus. Rheum. Dis. Clin. North Amer. 1994; 20: 243–263
   PubMed Web of Science ®Google Scholar
• Fox R. I. Mechanism of action of hydroxychloroquine as an anti‐rheumatic drug. Semin. Arthritis Rheum. 1993; 23: 82–91
   PubMed Web of Science ®Google Scholar
• Reid P. A., Watts C. Cycling of cell surface MHC glycoproteins through primaquine‐sensitive intracellular compartments. Nature 1990; 346: 655–657
   PubMed Web of Science ®Google Scholar
• Gilman A. L., Beams F., Tefft M., Mazumder A. The effect of hydroxychloroquine on alloreactivity and its potential use for graft‐versus‐host disease. Bone Marrow Transplantation
   Web of Science ®Google Scholar
• Schultz K. R., Bader S. Effect of chloroquine on cytolytic T‐cell priming to minor histocompatibility antigens, graft‐versus‐host disease and T‐cell leukemia‐vaccine responses. Med. Ped. Onc. 1995; 25: 285
   Google Scholar
• Roder J. C., Argov S., Klein M., Petersson C., Kiessling R., Andersson K., Hansson M. target‐effector cell interaction in the natural killer cell system: V. Energy requirements, membrane integrity, and the possible role of lysosomal enzymes. Immunology 1983; 40: 107–116
   Google Scholar
• Schultz K. R., Bader S., Paquet J., Li W. Chloroquine treatment affects T cell priming to minor histocompatibility antigens and graft‐versus‐host disease. Blood 1995; 86: 4344–52
   PubMed Web of Science ®Google Scholar
• Ertel W., Morrison M. H., Ayala A., Chaudry I. H. Chloroquine attenuates hemorrhagic shock‐induced suppression of kupffer cell antigen presentation and major histocompatibility complex class II antigen presentation through blockade of tumor necrosis factor and prostaglandin release. Blood 1991; 78: 1781–188
   PubMed Web of Science ®Google Scholar
• Nelson D., Bader S., Schultz K. R. Synergy of chloroquine and cyclosporin A in vitro on T cell responses to minor histocompatibility antigen and tetanus toxoid. Blood 1995; 86(Supp I)224a
   Google Scholar
• Lam G. K. Y. The differential aspects of the linear isobole in the study of combined action of agents. Bull. Mathematical Biol. 1993; 55: 295–313
   PubMed Web of Science ®Google Scholar
• McChesney E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 1983; 75: 11–18
   PubMed Web of Science ®Google Scholar
• Tett S. E., Cutler D. J., Brown C. F. A dose‐ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. J. Chromatography. 1985; 344: 241–248
   PubMed Web of Science ®Google Scholar
• MacKenzie A. H. Pharmacologic actions of 4‐amino‐quinoline compounds. Am. J. Med. 1983; 75: 5–10
   PubMed Web of Science ®Google Scholar
• Miller D. R., Fiechtner J. J., Carpenter J. R., Brown R. R., Stroshane R. M., Stecher V. I. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthr. Rheum. 1987; 30: 567–571
   PubMed Web of Science ®Google Scholar
• Cutler D., MacIntyre A., Tett S. Pharmacokinetics of 4‐Aminoquinoline antimalarials. AAS 1988; 24: 142–157
   Google Scholar
• Kersley G. D. Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet 1959; 886–888
   PubMed Web of Science ®Google Scholar
• Avital A., Godfrey S., Maayan Ch., Diamant Y., Springer C. Chloroquine treatment of interstitial lung disease in children. Pediatr. Pulm. 1994; 18: 356–360
   PubMed Web of Science ®Google Scholar
• Mainland D., Sutcliffe M. Hydroxychloroquine sul‐fate in rheumatoid arthritis, a six month, double‐blind trial. Bulletin of the Rheumatic Diseases 1962; 13: 3897–290
   Google Scholar
• Wallace D. J. Antimalarial agents and lupus. Rheum. Dis. Clin. North Amer. 1994; 20: 243
   PubMed Web of Science ®Google Scholar
• LaSalle J. M., Hafler D. A. Tcell anergy. FASEB J. 1994; 8: 601–8
   PubMed Web of Science ®Google Scholar
• Lanzevecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937–44
   PubMed Web of Science ®Google Scholar
• Pichler W. J., Wyss-Coray. T cells as antigen‐presenting cells. Immunol. Today 1994; 15: 312–5
   PubMedGoogle Scholar
• Ho W. Y., Cooke M. P., Goodnow C. C., Davis M. M. Resting and anergic B cells are defective in CD28–dependent costimulation of naive CD4+ T cells. J. Exp. Med. 1994; 179: 1539–49
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Kurasawa K., Smith R., Eckhaus M. A., Cress R. E. Donor CD4–enriched cells of the Th2 cytokine phenotype regulate graft‐versus‐host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540–3549
   PubMed Web of Science ®Google Scholar
• Mamula M. J., Craft J. The expression of self determinants: implications for tolerance and autoimmunity. Current Opinion Immunology 1994; 6: 882–6
   PubMed Web of Science ®Google Scholar